Douglas A. Levine, MD
While precision medicine has been a modern go-to approach by physicians in various malignancies, it is demonstrating a particular benefit in ovarian cancer, especially using the method for clinical trial enrollment and in determining whether patients are eligible to receive treatment with PARP inhibitors, according to Douglas A. Levine, MD.
on Treatment Options in Ovarian Cancer, where he discussed the topic in greater detail.
OncLive: Can you provide an overview of your lecture?
: I talked about incorporating precision medicine into gynecologic cancers, particularly in ovarian cancer. I began by talking about different sequencing methods and how far we've come with sequencing from the Human Genome Project to The Cancer Genome Atlas Project and the application of sequencing and precision medicine in daily clinical care. Specifically, we gave some examples of how to use precision medicine to direct people toward clinical trials, both for ovarian cancer and endometrial cancer, and how to use precision medicine to stratify patients for treatment with PARP inhibitors.
What are the sequencing challenges currently being faced in the ovarian cancer landscape?
The good thing about precision medicine is that doing the actual sequencing is quite easy nowadays. We've gotten pretty good at sequencing, and there are some established laboratories [that are also good] at interpreting the sequencing. Now, it is the interpretation that remains much more challenging than the actual sequencing.
... to read the full story